木村 晋也 きむら しんや 先生

来歴等

略歴

1986年 自治医科大学医学部 卒業
1996年 医学博士 取得
2001年 京都大学医学部附属病院 輸血細胞治療部 助教
2009年 佐賀大学医学部内科学講座 教授
2014年 佐賀大学医学部附属病院 副病院長
2017年 佐賀大学医学部創薬科学講座 教授 （併任）
2018年 佐賀大学 エスタブリッシュドフェロー

論文

• Treatment-free remission following first-line dasatinib in patients with chronic myelogenous leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol, pii: S2352-3026(19)30235-2, 2020.

  Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, Tanaka H, Shindo M, Kumagai T, Ikezoe T, Uoshima N, Sato T, Watanabe R, Kowata S, Hayakawa M, Hosoki T, Ikeda K, Kobayashi T, Kakinoki Y, Nishimoto T, Takezako N, Shibayama H, Takaori-Kondo A, Nakamae H, Kawaguchi A, Ureshino H, Sakamoto J, Ishida Y.

• Phosphorylated ERK1/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation. Blood Adv, in press.

  Itamura H, Shindo T, Yoshida S, Ishikawa T, Kimura S.

• Feasibility of the Imatinib Stop Study in the Japanese Clinical Setting: Delightedly Overcome CML Expert Stop TKI Trial (DOMEST Trial). Int J Clin Oncol, 24: 445-453, 2019.

  Fujisawa S, Ueda Y, Usuki K, Kobayashi K, Kondo E, Doki N, Nakao T, Kanda Y, Kosugi N, Kosug H, Kumagai T, Harada H, Shikami M, Maeda Y, Sakura T, Inokuchi K, Saito A, Nawa Y, Ogasawara M, Nishida J, Kondo T, Yoshida C, Kuroda H, Tabe Y, Maeda Y, Imajo K, Kojima K, Morita S, Komukai S, Kawaguchi A, Sakamoto J, Kimura S.

• Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML. Cancer Immunol Res, 6: 745-754, 2018.

  Ureshino H, Shindo T, Kojma H, Kusunoki Y, Miyazaki Y, Tanaka H, Saji H, Kawaguchi A, Kimura S.

• The MEK Inhibitor Trametinib Separates Murine Graft-versus-Host Disease from Graft-versus-Tumor Effects. J Clin Invest Insight, 1: e86331, 2016.

  Itamura H, Shindo T, Tawara I, Kubota Y, Kariya R, Okada S, Komanduri KV, Kimura S.

• Effector regulatory T cells reflects antitumor immunity and autoimmunity. Cancer Immunol Res, 4: 644-649, 2016.

  Ureshino H, Shindo T, Nishikawa H, Watanabe N, Watanabe E, Satoh N, Kitaura K, Kitamura H, Doi K, Nagase K, Kimura H, Sakurai R, Baba R, Kurogi K, Samukawa M, Kusunoki S, Miyahara M, Suzuki R, Sakaguchi S, Kimura S.

• Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study. Cancer Sci, 107: 162-167, 2016.

  Sueoka-Aragane N, Katakami N, Miyako M, Yokota S, Aoe K, Iwanaga K, Otsuka K, Morita S, Kimura S, Negoro S.

• Discontinuation of dasatinib in chronic myeloid leukaemia patients who have maintained deep molecular response for more than 1 year: the prospective, multicentre Dasatinib Discontinuation (DADI) Trial. Lancet Haematology, 2: e528-523, 2015.

  Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Morita S, Sakamoto J, Kimura S.

• NK314 potentiates anti-tumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase IIa and DNA-dependent protein kinase. Blood, 117: 3575-3584, 2011.

  Hisatomi T, Sueoka-Aragane N, Sato A, Tomimasu R, Ide M, Kunimasa A, Okamoto K, Kimura S, Sueoka E.

• Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells. Blood, 116: 2089-2095, 2010.

  Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T, Takeuchi M, Yao H, Reule M, Smyth T, Lyon JF, Thompson NT, Ashihara E, Ottmann OG, Maekawa T.

• Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in hypoxic environment. Cell Death Diff, 17: 1211-1220, 2010.

  Takeuchi M, Kimura S, Kuroda J, Ashihara E, Kawatani M, Osada H, Umezawa K, Yasui E, Imoto M, Tsuruo T, Yokota A, Tanaka R, Nagao R, Nakahara T, Fujiyama Y, Maekawa T.

• Phase I study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias post-imatinib resistance or intolerance. Cancer, 16: 2665-2672, 2010.

  Kantarjian H, le Coutre P, Cortes J, Pinilla-lbarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O.

• INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system and cyclosporine A augments its in vivo activity. Blood 109: 306-314, 2007.

  Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T

• NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106: 3948-3954, 2005.

  Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Nasu K, Asaki T, Niwa T, Hirabayashi K, Maekawa T.

• The third-generation bisphosphonate Zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 102: 2229-2235, 2003.

  Kuroda J, Kimura S, Segawa H, Kobayashi Y, Yoshikawa T, Urasaki Y, Ueda T, Enjo F, Tokuda H, Ottmann OG, Maekawa T.

• Nephrotic syndrome with crescent formation and massive IgA deposition following allogeneic bone marrow transplantation for natural killer cell leukemia/lymphoma. Blood 101: 4219-4221, 2003.

  Kimura S, Horie A, Hiki Y, Yamamoto C, Suzuki S, Kuroda J, Deguchi M, Kato GI, Karasuno T, Hiraoka A, Yoshikawa T, Maekawa T.

• Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci USA 95: 1195-1200, 1998

  Kimura S, Roberts AW, Metcalf D, Alexander WS.

• Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res 55: 1379-1384, 1995.

  Kimura S, Maekawa T, Hirakawa K, Murakami A, Abe T.

その他

• 【受賞】2012年　バイオビジネスアワード

• 【受賞】2018年　日本癌分子標的治療学会学術賞（鶴尾 隆賞）

• 【受賞】2019年　佐賀大学 学長賞

SNS・ブログ等

• その他メディア
  • 佐賀大学医学部附属病院 血液・呼吸器・腫瘍内科 医局HP
  • インターネット動画配信「もっと知ってほしい血液のがんのこと」